The Conversation (0)
More Featured Articles and Inverviews
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its lead neuroprotective peptide candidate, ARG007 improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.
Latest News
Latest News
Outlook Reports world
Featured Biotech Investing Stocks
Browse Companies
MARKETS
COMMODITIES
CURRENCIES
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.